RenovoRx Stock (NASDAQ:RNXT)
Previous Close
$1.35
52W Range
$0.77 - $1.86
50D Avg
$1.30
200D Avg
$1.18
Market Cap
$32.64M
Avg Vol (3M)
$90.31K
Beta
0.99
Div Yield
-
RNXT Company Profile
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.
RNXT Performance
Peer Comparison
| Ticker | Company |
|---|---|
| LGVN | Longeveron Inc. |
| ANEB | Anebulo Pharmaceuticals, Inc. |
| ELDN | Eledon Pharmaceuticals, Inc. |
| NTRB | Nutriband Inc. |
| ADIL | Adial Pharmaceuticals, Inc. |
| TPST | Tempest Therapeutics, Inc. |
| VRAX | Virax Biolabs Group Limited |
| MNPR | Monopar Therapeutics Inc. |
| SABS | SAB Biotherapeutics, Inc. |
| QNRX | Quoin Pharmaceuticals, Ltd. |
| KTTA | Pasithea Therapeutics Corp. |
| IKNA | Ikena Oncology, Inc. |